The IP argument is rubbish. Publishing peer reviewed studies actually strengthens IP as it clearly establishes prior art.
And I could understand this strategy if RCE were going balls-to-the-wall getting P2 -> P3 trials ramped up and recruited.
But as we know they are just spinning up endless phase 1 trials that get abandoned, chasing new indications, collecting fat salaries with nothing to show from anything.
The IP argument is rubbish. Publishing peer reviewed studies...
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.020(4.17%) |
Mkt cap ! $104.3M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 47.5¢ | 45.0¢ | $51.12K | 110.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 56280 | 1 |
View Market Depth
| Last trade - 15.57pm 19/11/2024 (20 minute delay) ? |
| RCE (ASX) Chart |